In genetically engineered MM mouse models, early transgenic activation of the MYC oncogene was associated with enhanced numbers of MM infiltrating PD-1+ TIGIT+ LAG3+ CD8+ T cells, whereas late MYC activation was linked to significantly decreased numbers of activated/exhausted CD8+ T cells (165). Here, MYC is linked to Miyoshi myopathy.